Go for three.

Efficacy Matters, Choose OMNI^®

Learn More

The Challenge

In eyes with open-angle glaucoma, identifying where blockage or resistance occurs within the conventional outflow pathway can be hard.

Targeting the trabecular meshwork alone, or isolating a single point, may not be enough to lower IOP.

75% of Surgeons want to address the conventional outflow pathway first¹

Between 50-75% of resistance may be in the Trabecular Meshwork^2,3,4

Up to 50% of resistance may be in Schlemm’s canal and the distal collector channels^2,3,4

The Solution

OMNI^® targets all three points of resistance.

Trabecular meshwork
trabeculotomy

Schlemm’s canal
canaloplasty

Collector channels
canaloplasty

ONE MIGS device

TWO implant-free procedures

THREE points of resistance

Learn More

Meet the next generation OMNI^® Surgical System.

With the OMNI^® Surgical System, you can perform two implant-free procedures targeting three points of resistance with one intelligent device.

Two procedures in one
intelligently designed device.

The OMNI^® Surgical System is indicated for the catheterization and transluminal viscodilation of Schlemm's canal and the cutting of trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma.

Canaloplasty

With its unique implant-free approach, the OMNI^® Surgical System lets you access Schlemm’s canal with the microcatheter through a single clear corneal incision. Intelligently engineered with an internal reservoir delivering a controlled amount of viscoelastic fluid.

Trabeculotomy

To address the trabecular meshwork as a point of resistance within the conventional outflow pathway, the OMNI^® Surgical System lets you perform a trabeculotomy customized to meet your surgical plan.

Summary of the Evidence

DEMONSTRATED IOP REDUCTION WHEN COMBINED WITH CATARACT SURGERY

24 EYES: TRABECULOTOMY AND CANALOPLASTY IN MILD/MODERATE EYES WITH OAG⁵

DEMONSTRATED IOP REDUCTION IN A STANDALONE PROCEDURE

38 EYES: TRABECULOTOMY AND CANALOPLASTY IN MILD/MODERATE EYES WITH POAG⁶

Upcoming Events

See Full list See Less list

News

September 16 , 2022

Sight Sciences OMNI® Surgical System to Be Featured in Multiple Presentations at the 2022 European Society of Cataract and Refractive Surgery Annual Meeting

March 30 , 2022

Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI^® Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma

November 10 , 2021

Sight Sciences Announces FDA Authorization for the PRECISION Trial, a Groundbreaking Three-Arm Randomized, Controlled IDE Trial of Canal Viscodilation in Combination with Cataract Surgery in Adults with Primary Open-Angle Glaucoma (POAG).

August 26 , 2021

Sight Sciences to Participate in the Morgan Stanley Global Healthcare Conference

August 24 , 2021

Sight Sciences, Pioneering the Development of the Standalone MIGS Market, Announces Publication of Favorable Two-Year Outcomes of Standalone Use of the OMNI® Surgical System in Mild to Moderate Open-Angle Glaucoma

December 01 , 2020

Sight Sciences Announces Substantial Crossover Raise

July 14 , 2020

Sight Sciences Appoints Donald J. Zurbay to Company’s Board of Directors

June 25 , 2020

Sight Sciences Strengthens Its Leadership Team with Chief Operating Officer and General Counsel Hires

March 30 , 2020

Sight Sciences Announces Publication of Historical Review of Canal Surgery in the Glaucoma Issue of Current Opinion in Ophthalmology

April 30 , 2019

Sight Sciences Announces Official Launches of TearCare^® and the Enhanced, Next Generation OMNI^® System

January 04 , 2018

Sight Sciences Expands Surgical Portfolio with FDA Clearance of the OMNI^™ Surgical System

Request more info about the
OMNI^® Surgical System

Inquiry type*

Specialty*

First Name*

Last Name*

Email Address*

Phone Number*

City*

Country*

Zip Code*

Information Requested*

Other Information Requested*

Are you a Cataract surgeon?*

YesNo

Do you provide post-op care?*

YesNo

Referral source*

By selecting the opt-in box and submitting information here, you acknowledge and agree to the terms of our Privacy Policy and understand that you may be contacted by Sight Sciences using the contact information provided.

Submit

Indications and Safety Information

Indications for use

The OMNI® Surgical System is indicated for the catheterization and transluminal viscodilation of Schlemm’s canal and the cutting of trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma.

Contraindications

1. Do not use the OMNI in any situations where the angle is compromised or has been damaged (e.g., from trauma or surgery), since it may not be possible to visualize the angle or to properly pass the microcatheter.
2. Do not use the OMNI in patients with angle recession; neovascular glaucoma; chronic angle closure; narrow-angle glaucoma; traumatic or malignant glaucoma; or narrow inlet canals with plateau iris.

Warnings

1. Do not use in cases where there is insufficient visibility to properly see the angle. The following conditions may prohibit sufficient visualization of the angle required for safe and successful cannula placement: corneal edema, corneal haze, corneal opacity, or any other conditions that may inhibit gonioscopic view of the angle and intended cannula entry location.
2. Perform gonioscopy prior to taking a patient to surgery to exclude congenital anomalies of the angle, anterior segment dysgeneses, peripheral anterior synechiae (PAS), rubeosis, and any other angle abnormalities that could lead to improper placement of the cannula and microcatheter and pose a hazard.
3. Maintain direct microscopic or gonioscopic visualization of the cannula tip and microcatheter tip at all times during the procedure to facilitate advancement and to avoid inadvertently damaging intraocular structures, kinking the microcatheter or unintended tearing of trabecular meshwork.

Potential adverse events

Adverse events that may be reasonably associated with the use of the OMNI® System in the eye include but are not limited to the following: anterior chamber shallowing, severe, prolonged, or persistent intraocular inflammation including toxic anterior segment syndrome (TASS), endophthalmitis or other ocular infection, aqueous misdirection, Descemet’s membrane tear or detachment, intracorneal hematoma, choroidal effusion, suprachoroidal hemorrhage, corneal decompensation, corneal injury, corneal edema or opacification, unintended trabeculotomy, cyclodialysis cleft, hyphema, hypopyon, hypotony, hypotony maculopathy, IOL dislocation, cataract formation, iris injury, tear, or iridodialysis, loss of vitreous, perforation of sclera, posterior capsular bag rupture, proliferative vitreoretinopathy, pupillary block, pupillary membrane formation, retinal detachment, retinal dialysis, retinal flap tears, secondary surgical intervention, including but not limited to glaucoma surgery, and vitreous hemorrhage.